2003—2015年北京医院门诊血管紧张素转化酶抑制剂的应用分析

Utilization of Angiotensin Converting Enzyme Inhibitors in Beijing Hospital from 2003 to 2015

目的了解2003—2015年北京医院门诊血管紧张素转化酶抑制剂(ACEI)类抗高血压药物使用情况及销售金额,为临床合理用药提供依据。方法对2003—2015年北京医院门诊ACEI类药物用药频度、销售量、销售金额、销售金额占全年销售金额的百分比进行分析。结果 2003—2015年北京医院门诊ACEI类降压药中,贝那普利10 mg销售金额一直较平稳且居第1位,福辛普利、进口雷米普利、培哚普利销售金额较为平稳,依那普利叶酸片自2011年进入北京医院以来,一直处于上升趋势。其他品种药物均处于相对平稳状态。结论北京医院门诊ACEI类抗高血压药物的销售基本稳定,使用合理,符合抗高血压药物的使用原则。

Objective To investigate the current application and sales status of angiotensin converting enzyme inhibitors(ACEI),and provide the reasonable and reliable evidence for clinical regimen.Methods We collected data from 2003 through 2015 about ACEI antihypertensive drugs’ usage frequency,sales,sales amount and the ratio of it compared with the whole sales amount from Beijing Hospital outpatient.After that,statistical analysis for these data was performed.Results It showed by the analysis that among Beijing Hospital outpatient ACEI antihypertensive drugs,Benazepril 10 mg hold the steady and top sales amount.Apart from this,the sales amounts of Fosinopril, Imported Ramipril and Perindopril were relatively stable.However,for enalapril maleate and folic acid tablets,the sales amount showed an escalating trend since 2011 when it was first introduced into our hospital. Except for this,the sales amounts for other categories were kept at comparatively steady status.Conclusion Beijing Hospital outpatient oral ACEI antihypertensive drug sales is basically stable,the use of reasonable,consistent with the principle of the use antihypertensive drugs.